POLARIS GROUP Business Summary

Polaris Group (6550.TW) is a multinational biopharmaceutical company specializing in metabolic-based cancer therapies, primarily targeting arginine-auxotrophic tumors. The company operates an integrated business model, generating revenue through its Contract Development and Manufacturing Organization (CDMO) services—managed via its subsidiary Genovior Biotech—and the production of active pharmaceutical ingredients (APIs) and peptide drugs. Its primary business segments include New Drug Development, focused on its lead biologic candidate ADI-PEG 20 (pegargiminase), and Biopharmaceutical Services, which encompasses end-to-end manufacturing for external partners. As of early 2026, the company is transitioning toward commercialization following the FDA’s substantive review of its Biologics License Application (BLA) for ADI-PEG 20 in malignant pleural mesothelioma and the recent termination of its NASH clinical trials to consolidate resources. Direct competitors include Tanvex BioPharma (6541.TW), Mycenax Biotech (4726.TW), and Gongwin Biopharm (6617.TW), with Polaris positioning itself as a vertically integrated leader in the niche metabolic oncology market. The company is led by Chairman and CEO Samuel Chen (Chen Shyan-Tser), a billionaire venture capitalist and early investor in Zoom Video Communications, who assumed the CEO role in December 2025 to oversee a strategic realignment. The executive leadership team features Chief Operating Officer Dr. Hugh Yu, a CMC expert with extensive experience in biologics development and regulatory BLA submissions, and Executive Vice President of Medical Affairs Dr. John Bomalaski, a co-founder of Phoenix Pharmacologics who has spearheaded the clinical development of ADI-PEG 20 for over three decades. Notable financial backing and board control are maintained by Chen’s investment vehicles, Digital Capital Inc. and Digital Mobile Venture, which hold a combined majority stake of approximately 55%. Other significant institutional investors include The Vanguard Group and BlackRock, supporting the company's capital structure as it approaches potential commercial-stage operations.